Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Lynn Williams breaks NWSL goal
Lynn Williams scored her 79th league goal, becoming the National Women’s Soccer League all-time scor2024-05-21Australia to host 2026 AFC Women's Asian Cup
Football Australia (FA) has celebrated the country being awarded the hosting rights for the 2026 Asi2024-05-21Europeans flock to China with visa
Under a visa-free entry policy effective from Friday, ordinary passport holders from France, Germany2024-05-21Brazil halts top football league as flooding death toll rises
The Brazilian Football Confederation (CBF) has postponed the next two rounds of the country's to2024-05-21Dodgers acquire pitcher Yohan Ramírez from Mets for cash
LOS ANGELES (AP) — The Los Angeles Dodgers acquired pitcher Yohan Ramírez from the New York Mets for2024-05-21Shanghai kicks off Olympic qualifying
Sunshine, exuberance, great athleticism. The Olympic Qualifying Series Shanghai kicked off in grand2024-05-21
atest comment